9DRQ image
Deposition Date 2024-09-26
Release Date 2025-02-19
Last Version Date 2025-02-19
Entry Detail
PDB ID:
9DRQ
Keywords:
Title:
Mumps virus fusion glycoprotein F stabilized in prefusion conformation
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.16 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
H 3 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F0
Chain IDs:A
Chain Length:441
Number of Molecules:1
Biological Source:Mumps orthorubulavirus
Ligand Molecules
Primary Citation
Structure-based design of glycoprotein subunit vaccines for mumps.
Proc.Natl.Acad.Sci.USA 121 e2404053121 e2404053121 (2024)
PMID: 39527740 DOI: 10.1073/pnas.2404053121

Abstact

Mumps virus (MuV) is a highly contagious paramyxovirus that is endemic in most regions of the world and continues to cause outbreaks even in highly immunized populations. Outbreaks of mumps in countries with high measles, mumps, and rubella vaccination coverage have been attributed to waning immunity and antigenic differences between the Jeryl Lynn vaccine strain (genotype A) and circulating wild-type viruses. To obtain a subunit vaccine, we used structure-based design to engineer the mumps fusion (F) glycoprotein stabilized in its prefusion conformation (Pre-F) as well as a chimeric immunogen comprising Pre-F linked to mumps hemagglutinin neuraminidase (HN); in mice, both Pre-F antigen and the chimeric antigen elicited potent cross-reactive plaque reducing neutralizing titers to genotypes A, G, and H mumps. A crystal structure of mumps Pre-F at 2.16 Å resolution validated the stabilization strategy, while a post-fusion form of F was engineered as a comparator. Monoclonal antibodies to mumps Pre-F and HN were isolated from immunized mice; 7 of 14 Pre-F-specific antibodies and 9 of 15 HN-specific antibodies were capable of neutralizing genotype G MuV with a range of potencies. Additionally, 7 of 14 Pre-F-specific antibodies neutralized genotype A mumps. Structural and binding analyses of Pre-F-specific antibodies revealed binding to four discrete neutralizing antigenic sites and binding analyses of HN-specific antibodies revealed binding to five discrete neutralizing antigenic sites. Overall, the PreF and the chimeric Pre-F/HN immunogens are promising candidates to boost MMR-elicited immunity to mumps or as a next-generation vaccine.

Legend

Protein

Chemical

Disease

Primary Citation of related structures